Hjem
  • E-postTone.Bjorge@uib.no
  • Telefon+47 55 58 85 30+47 995 35 990
  • Besøksadresse
    Alrek helseklynge, blokk D, Årstadveien 17
  • Postadresse
    Postboks 7804
    5020 Bergen

Kreftepidemiologi

  • Underviser på kurs i epidemiologi for medisin- og PhD studenter
  • Veileder medisinstudenter (særoppgave), PhD studenter og postdoktorer
Vitenskapelig artikkel
  • Vis forfatter(e) 2021. Prescribed drugs in 27 000 individuals after diagnosis of colorectal cancer: A population-based cohort study. Pharmacoepidemiology and Drug Safety. 1037-1048.
  • Vis forfatter(e) 2021. Metabolic factors and the risk of small intestine cancers: Pooled study of 800 000 individuals in the metabolic syndrome and cancer project. International Journal of Cancer. 1-9.
  • Vis forfatter(e) 2021. Cervical cancer in women under 30 years of age in Norway: a population-based cohort study. BMC Women's Health. 8 sider.
  • Vis forfatter(e) 2020. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 582-597.
  • Vis forfatter(e) 2020. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. British Journal of Cancer. 1715-1723.
  • Vis forfatter(e) 2020. Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study. British Journal of Cancer. 161-166.
  • Vis forfatter(e) 2020. Maternal use of folic acid and multivitamin supplements and infant risk of birth defects in Norway, 1999–2013. British Journal of Nutrition. 316-329.
  • Vis forfatter(e) 2020. Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study. The Lancet Diabetes and Endocrinology. 94-105.
  • Vis forfatter(e) 2020. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. The Lancet. 1160-1203.
  • Vis forfatter(e) 2020. Five insights from the Global Burden of Disease Study 2019. The Lancet. 1135-1159.
  • Vis forfatter(e) 2020. Cancer risk in individuals with major birth defects: large Nordic population based case-control study among children, adolescents, and adults. The BMJ. 14 sider.
  • Vis forfatter(e) 2020. Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State. Acta Oncologica. 949-958.
  • Vis forfatter(e) 2019. The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. International Journal of Epidemiology. 93-104.
  • Vis forfatter(e) 2019. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 934-947.
  • Vis forfatter(e) 2019. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 913-933.
  • Vis forfatter(e) 2019. Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals. International Journal of Cancer. 58-67.
  • Vis forfatter(e) 2019. Life expectancy and disease burden in the Nordic countries: results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. The Lancet Public Health. e658-e669.
  • Vis forfatter(e) 2019. BMI and weight changes and risk of obesity-related cancers: a pooled European cohort study. International Journal of Epidemiology. 1872-1885.
  • Vis forfatter(e) 2019. Atypical glandular lesions of the cervix and risk of cervical cancer. Acta Obstetricia et Gynecologica Scandinavica. 1-9.
  • Vis forfatter(e) 2019. Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: A Nordic population-based case-control study. International Journal of Cancer. 1-10.
  • Vis forfatter(e) 2018. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiology and Drug Safety. 995-1004.
  • Vis forfatter(e) 2018. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. Journal of Internal Medicine. 430-445.
  • Vis forfatter(e) 2018. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. International Journal of Cancer. 3071-3082.
  • Vis forfatter(e) 2018. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. International Journal of Cancer. 1858-1867.
  • Vis forfatter(e) 2018. Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population-based case-control study. International Journal of Cancer. 1904-1913.
  • Vis forfatter(e) 2018. Paternal characteristics associated with maternal periconceptional use of folic acid supplementation. BMC Pregnancy and Childbirth. 1-8.
  • Vis forfatter(e) 2018. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer. 1028-1035.
  • Vis forfatter(e) 2018. Human papillomavirus type specific risk of progression and remission during long-term follow-up of equivocal and low-grade HPV-positive cervical smears. International Journal of Cancer. 851-860.
  • Vis forfatter(e) 2018. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 1859-1922.
  • Vis forfatter(e) 2018. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. . The Lancet. 1923-1994.
  • Vis forfatter(e) 2018. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 1015-1035.
  • Vis forfatter(e) 2018. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk. Cancer Research. 274-285.
  • Vis forfatter(e) 2017. Suicide and violent deaths in survivors of cancer in childhood, adolescence and young adulthood-a national cohort study. International Journal of Cancer. 575-580.
  • Vis forfatter(e) 2017. Preterm births and use of medication in early adulthood: a population-based registry study. Pharmacoepidemiology and Drug Safety. 742-751.
  • Vis forfatter(e) 2017. HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia. Gynecologic Oncology. 111-117.
  • Vis forfatter(e) 2017. Cohort Profile Update: The Janus Serum Bank Cohort in Norway. International Journal of Epidemiology. 1101-1102f.
  • Vis forfatter(e) 2016. Supplemental folic acid in pregnancy and childhood cancer risk. British Journal of Cancer. 71-75.
  • Vis forfatter(e) 2016. Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case–control study. British Journal of Cancer. 1416-1420.
  • Vis forfatter(e) 2016. Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study. British Journal of Cancer. 348-356.
  • Vis forfatter(e) 2016. Long Term Association between Serum 25-Hydroxyvitamin D and Mortality in a Cohort of 4379 Men. PLOS ONE. 11 sider.
  • Vis forfatter(e) 2016. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
  • Vis forfatter(e) 2016. Educational attainment among long-term survivors of cancer in childhood and adolescence: a Norwegian population-based cohort study. Journal of cancer survivorship. 87-95.
  • Vis forfatter(e) 2016. Economic independence in survivors of cancer diagnosed at a young age: A Norwegian national cohort study. Cancer. 3873-3882.
  • Vis forfatter(e) 2016. Circulating folate and vitamin B12 and risk of prostate cancer: a collaborative analysis of individual participant data from six cohorts including 6875 cases and 8104 controls. European Urology. 941-951.
  • Vis forfatter(e) 2016. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstetrics and Gynecology. 1265-1273.
  • Vis forfatter(e) 2015. Supplemental folic acid in pregnancy and maternal cancer risk. Cancer Epidemiology. 805-811.
  • Vis forfatter(e) 2015. Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme. Acta Oncologica. 200-209.
  • Vis forfatter(e) 2015. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Epidemiology (EJE). 501-508.
  • Vis forfatter(e) 2015. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. International Journal of Epidemiology. 1353-1363.
  • Vis forfatter(e) 2015. Folic acid supplements and risk of oral clefts in the newborn: A population-based study. British Journal of Nutrition. 1456-1463.
  • Vis forfatter(e) 2014. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer – a large nested case-control study within the JANUS cohort in Norway. International Journal of Cancer. 197-206.
  • Vis forfatter(e) 2014. Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology. 823-828.
  • Vis forfatter(e) 2014. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes and Control. 151-159.
  • Vis forfatter(e) 2014. Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Oncology. 1609-1615.
  • Vis forfatter(e) 2014. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: A prospective study of 580 000 subjects within the Me-Can project. BMC Cancer. 12 sider.
  • Vis forfatter(e) 2014. A prospective study on metabolic risk factors and gallbladder cancer in the metabolic syndrome and cancer (Me-Can) collaborative study. PLOS ONE.
  • Vis forfatter(e) 2013. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. American Journal of Clinical Nutrition. 147-154.
  • Vis forfatter(e) 2013. Total serum cholesterol and cancer incidence in the Metabolic Syndrome and Cancer Project (Me-Can). PLOS ONE. 8 sider.
  • Vis forfatter(e) 2013. The Healthy Worker Effect in Cancer Incidence Studies. American Journal of Epidemiology. 1218-1224.
  • Vis forfatter(e) 2013. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk-a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. International Journal of Epidemiology. 201-210.
  • Vis forfatter(e) 2013. Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control. 107-116.
  • Vis forfatter(e) 2013. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes and Control. 151-159.
  • Vis forfatter(e) 2013. Metabolic Factors Associated with Risk of Renal Cell Carcinoma. PLOS ONE.
  • Vis forfatter(e) 2013. Increased uptake of social security benefits among long-term survivors of cancer in childhood, adolescence and young adulthood: a Norwegian population-based cohort study. British Journal of Cancer. 1525-1533.
  • Vis forfatter(e) 2013. HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway. Cancer Medicine. 182-189.
  • Vis forfatter(e) 2013. Fetal growth and childhood cancer: A population-based study. Pediatrics. E1265-E1275.
  • Vis forfatter(e) 2013. Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340,000 pregnancies using Norwegian population-based databases. British Journal of Clinical Pharmacology. 1134-1141.
  • Vis forfatter(e) 2012. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 6199-6206.
  • Vis forfatter(e) 2012. Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can). British Journal of Dermatology. 59-67.
  • Vis forfatter(e) 2012. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. International Journal of Cancer. 193-200.
  • Vis forfatter(e) 2012. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecologic Oncology. 330-335.
  • Vis forfatter(e) 2012. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Annals of Hematology. 1519-1531.
  • Vis forfatter(e) 2012. Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes and Control. 1297-1305.
  • Vis forfatter(e) 2012. Blood pressure and risk of cancer incidence and mortality in the Metabolic syndrome and cancer project. Hypertension. 802-810.
  • Vis forfatter(e) 2012. Blood pressure and other metabolic syndrome factors and risk of brain tumor in the large population-based Me-Can cohort study. Journal of Hypertension. 290-296.
  • Vis forfatter(e) 2011. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes and Control. 291-299.
  • Vis forfatter(e) 2011. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. European Journal of Epidemiology (EJE). 157-163.
  • Vis forfatter(e) 2011. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). International Journal of Cancer. 1890-1898.
  • Vis forfatter(e) 2011. Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can). Annals of Oncology. 1339-1345.
  • Vis forfatter(e) 2011. Metabolic risk factors and ovarian cancer in the Metabolic syndrome and cancer project. International Journal of Epidemiology. 1667-1677.
  • Vis forfatter(e) 2011. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control. 743-751.
  • Vis forfatter(e) 2011. Metabolic Factors and the Risk of Colorectal Cancer in 580,000 Men and Women in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer. 2398-2407.
  • Vis forfatter(e) 2011. Maternal birth characteristics and perinatal mortality in twin offspring. An intergenerational population-based study in Norway, 1967-2008. BJOG: An International Journal of Obstetrics and Gynaecology. 698-705.
  • Vis forfatter(e) 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Vis forfatter(e) 2011. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety. 243-248.
  • Vis forfatter(e) 2011. Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiology, Biomarkers and Prevention. 1726-1735.
  • Vis forfatter(e) 2010. Trends in incidence and mortality for triplets in Norway 1967-2006: the influence of assisted reproductive technologies. BJOG: An International Journal of Obstetrics and Gynaecology. 667-675.
  • Vis forfatter(e) 2010. Metabolic syndrome and endometrial carcinoma. American Journal of Epidemiology. 892-902.
  • Vis forfatter(e) 2010. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiology, Biomarkers and Prevention. 1737-1745.
  • Vis forfatter(e) 2010. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiology, Biomarkers and Prevention. 2307-2317.
  • Vis forfatter(e) 2010. Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occupational and Environmental Medicine. 335-340.
  • Vis forfatter(e) 2010. Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). International Journal of Epidemiology. 660-667.
  • Vis forfatter(e) 2009. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 1083-1089.
  • Vis forfatter(e) 2009. Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occupational and Environmental Medicine.
  • Vis forfatter(e) 2009. Fetal down syndrome and the risk of maternal breast cancer. Epidemiology. 584-589.
  • Vis forfatter(e) 2009. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Medicine. 14 sider.
  • Vis forfatter(e) 2008. Cancer risk in children with birth defects and in their families: A population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiology, Biomarkers and Prevention. 500-506.
  • Vis forfatter(e) 2008. Body mass index in adolescence in relation to cause-specific mortality: A follow-up of 230,000 Norwegian adolescents. American Journal of Epidemiology. 30-37.
  • Vis forfatter(e) 2008. Birth and parental characteristics and risk of neuroblastoma in a population-based Norwegian cohort study. British Journal of Cancer. 1165-1169.
  • Vis forfatter(e) 2007. Increasing twinning rates in Norway, 1967-2004: the influence of maternal age and assisted reproductive technology (ART). Acta Obstetricia et Gynecologica Scandinavica. 833-839.
  • Vis forfatter(e) 2007. Height and body mass index and risk of lymphohematopoietic malignancies in two million norwegian men and women. American Journal of Epidemiology. 44-52.
  • Vis forfatter(e) 2007. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. International Journal of Cancer. 378-383.
  • Vis forfatter(e) 2006. The impact of height and body mass index on the risk of testicular cancer in 600,000 Norwegian men. Cancer Causes and Control. 983-987.
  • Vis forfatter(e) 2006. Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
  • Vis forfatter(e) 2005. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes and Control. 987-996.
  • Vis forfatter(e) 2005. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. British Journal of Cancer. 807-810.
  • Vis forfatter(e) 2005. Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecologic Oncology. 733-739.
  • Vis forfatter(e) 2004. p16(INK4a) and p21(Waf1/Cip1) expression correlates with clinical outcome in vulvar carcinomas. Gynecologic Oncology. 37-45.
  • Vis forfatter(e) 2004. Obesity in adolescence and adulthood and the risk of adult mortality. Epidemiology. 79-85.
  • Vis forfatter(e) 2004. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. European Journal of Cancer. 1058-1065.
  • Vis forfatter(e) 2004. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. European Journal of Cancer. 1058-1065.
  • Vis forfatter(e) 2004. Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Analytical Chemistry. 4406-4409.
  • Vis forfatter(e) 2004. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. British Journal of Cancer. 1829-34.
  • Vis forfatter(e) 2003. Height, body mass index and prostate cancer: a follow-up of 950 000 Norwegian men. British Journal of Cancer. 1237-1242.
  • Vis forfatter(e) 2003. Height, body mass index and ovarian cancer: a follow-up of 1.1 million Norwegian women. Journal of the National Cancer Institute. 1244-1248.
  • Vis forfatter(e) 2002. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. British Journal of Cancer. 61-64.
  • Vis forfatter(e) 2002. Gestational trophoblastic tumors in Norway, 1968-1997: Patient characteristics, treatment and prognosis. Gynecologic Oncology. 71-76.
  • Vis forfatter(e) 2002. Bruk av p-piller og risiko for kreft. Tidsskrift for Den norske legeforening. 1788-1790.
  • Vis forfatter(e) 2001. kan testing og vaksinering for humant papillomavirus forebygge livmorhalskreft. Tidsskrift for Den norske legeforening. 2947-2951.
  • Vis forfatter(e) 2001. Kan testing og vaksinering av humant papillomavirus forebygge livmorhalskreft? Tidsskrift for Den norske legeforening. 2947-51.
  • Vis forfatter(e) 2000. Ovarialcancerscreening. Tidsskrift for Den norske legeforening. 1440-1448.
  • Vis forfatter(e) 2000. Chlamydia trachomatis infection as a risk factor for invasive cervical carcinoma. International Journal of Cancer. 35-39.
  • Vis forfatter(e) 2000. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. International Journal of Cancer. 35-39.
  • Vis forfatter(e) 1999. Screening mot kreft. Tidsskrift for Den norske legeforening. 1129-1136.
  • Vis forfatter(e) 1999. No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. International Journal of Cancer. 818-22.
  • Vis forfatter(e) 1998. Prognosis of patients with Ovarian Cancer and Borderline Tumours Diagnosed in Norway between 1954 and 1993. International Journal of Cancer. 663-670.
  • Vis forfatter(e) 1998. Prognosis of 2.800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstetricia et Gynecologica Scandinavica. 777-781.
  • Vis forfatter(e) 1998. Ovarialcancer og borderlinetumorer. Tidsskrift for Den norske legeforening. 2471-2475.
  • Vis forfatter(e) 1998. Ovarialcancer og borderlinetumorer. Tidsskrift for Den norske legeforening. 2471-2475.
  • Vis forfatter(e) 1997. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-93. Acta Obstetricia et Gynecologica Scandinavica. 606.
  • Vis forfatter(e) 1997. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. International Journal of Cancer. 780-786.
  • Vis forfatter(e) 1997. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ. British Medical Journal. 646-649.
  • Vis forfatter(e) 1997. Prospective seroepidemiologic study of human papilloma virus infection as a risk factor for invasive cervical cancer. Journal of the National Cancer Institute. 1293-1299.
  • Vis forfatter(e) 1997. Prognosis of 3,000 Patients with Epithelial Ovarian Cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Society of Pelvic Surgeons: Forty-seventh annual meeting. 35.
  • Vis forfatter(e) 1997. Ovarian Cancer-Are we making progress? European Journal of Cancer. 621.
  • Vis forfatter(e) 1997. Hormonell substitusjonsbehandling og kreft. Tidsskrift for Den norske legeforening. 2201-2207.
  • Vis forfatter(e) 1997. A Prospective, Seroepidemiological Study of the Role of Human Papillomavirus in Esophageal Cancer in Norway. Cancer Research. 3989-3992.
  • Vis forfatter(e) 1996. Reproductive variables and risk of uterine cervical cancer in Norwegian registry data. Cancer Causes and Control. 351-357.
  • Vis forfatter(e) 1996. Reproductive factors and prognosis of uterine cervical cancer in Norway. British Journal of Cancer. 1843-1846.
Rapport
  • Vis forfatter(e) 2012. Årstabeller for Medisinsk fødselsregister 2010 Fødsler i Norge. 2012. 2012. .
  • Vis forfatter(e) 2011. Årstabeller for Medisinsk fødselsregister 2009. Fødsler i Norge. 2011. 2011. .
  • Vis forfatter(e) 2011. Årsrapport for Medisinsk fødselsregister 2009. Fødsler i Norge. 2009. 2009. .
  • Vis forfatter(e) 2011. Sekundærscreening med HPV-tester i Masseundersøkelsen mot livmorhalskreft. .
  • Vis forfatter(e) 2002. Trofoblast tumorer i Norge 1968-97. Pasientkarakteristika, behandling og prognose. .
Vitenskapelig foredrag
  • Vis forfatter(e) 2007. Medfødte misdannelser og kreft, felles årsaksbakgrunn?
  • Vis forfatter(e) 2000. The joint effects of sexually transmitted infections on the risk of cervical cancer.
Leserinnlegg
  • Vis forfatter(e) 2006. Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases. Histopathology. 311-312.
Short communication
  • Vis forfatter(e) 2005. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. British Journal of Cancer. 807-810.
Populærvitenskapelig artikkel
  • Vis forfatter(e) 2012. HPV-evalueringen – så rettferdig som mulig. Dagens medisin.
  • Vis forfatter(e) 2011. HPV-evalueringen: Ingen særbehandling av enkelttester. Dagens medisin.
  • Vis forfatter(e) 2011. HPV-evaluering: Ekstra celleprøve kompenserer ikke for lav sensitivitet på den norske testen. Dagens medisin.
Kronikk
  • Vis forfatter(e) 2010. Parodisk personvern. Dagbladet.
Brev til redaktøren
  • Vis forfatter(e) 2006. Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases. Histopathology. 311-312.
Doktorgradsavhandling
  • Vis forfatter(e) 2019. Folic acid in pregnancy and subsequent cancer risk in mothers and their children: An epidemiologic study in Norway, 1999–2010.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) 2011. Special Issue: Cancer Screening in Norway, 2011. 12 sider.
Sammendrag/abstract
  • Vis forfatter(e) 2012. Metabolic syndrome and cervical cancer in the Metabolic Syndrome and Cancer Project (Me-Can). Journal of Women's Health. 39-39.
  • Vis forfatter(e) 2011. The Strength of the Healthy Worker Effect Varies According to the Type of Cancer Being Studied. Epidemiology. S261-S262.
  • Vis forfatter(e) 2011. TOTAL SERUM CHOLESTEROL AND CANCER INCIDENCE IN THE METABOLIC SYNDROME AND CANCER PROJECT (ME-CAN). Journal of Epidemiology and Community Health. A302-A302.
  • Vis forfatter(e) 2011. METABOLIC SYNDROME AND RISK OF BRAIN TUMOUR IN A LARGE POPULATION-BASED COHORT STUDY. Journal of Epidemiology and Community Health. A238-A239.
  • Vis forfatter(e) 2011. METABOLIC SYNDROME AND CERVICAL CANCER IN THE METABOLIC SYNDROME AND CANCER PROJECT (ME-CAN). Journal of Epidemiology and Community Health. A279-A279.
  • Vis forfatter(e) 2007. Twinning and triplet rates in Norway, 1967-2004. Human Reproduction. S30.
Errata
  • Vis forfatter(e) 2013. Erratum to: Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes and Control. 2253-2256.
  • Vis forfatter(e) 2004. Corrigendum. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. British Journal of Cancer. 1226.

Se fullstendig oversikt over publikasjoner i CRIStin.

20 utvalgte publikasjoner:

 

1.Bjørge T, Dillner J, Anttila T, Engeland A, Hakulinen T, Jellum E, Lehtinen M, Luostarinen T, Paavonen J, Pukkala E, Sapp M, Schiller J, Youngman L, Thoresen S. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ 1997; 315: 646-9.

 

2.Bjørge T, Hakulinen T, Engeland A, Jellum E, Koskela P, Lehtinen M, Luostarinen T, Paavonen J, Sapp M, Schiller J, Thoresen S, Wang Z, Youngman L, Dillner J. A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res 1997; 57: 3989-92.

 

3. Dillner J, Lehtinen M, Bjørge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller J, Hakulinen T, Thoresen S, Hakama M. A prospective, seroepidemiological study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997; 89: 1293-9.

 

4. Bjørge T, Engeland A, Hansen S, Tropé CG. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 1998; 75: 663-70.

 

5. Engeland A, Tretli S, Bjørge T. Height, body mass index, and ovarian cancer - a follow-up of 1,1 million Norwegian women. J Natl Cancer Inst 2003; 95: 1244-8.

 

6. Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004; 91: 1829-34.

 

7.Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol 2004; 160: 1168-76.

 

8. Bjørge T, Engeland A, Tretli, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2007; 120: 378-83.

 

9. Engeland A, Tretli S, Hansen S, Bjørge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol 2007; 165: 44-52.

 

10. Bjørge T, Cnattingius S, Lie RT, Tretli S, Engeland A. Cancer risk in families of children with birth defects. A population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiol Biomarkers Prev 2008; 17: 500-6.

 

11. Bjørge T, Engeland A, Tverdal A, Davey Smith G. Body mass index in adolescence in relation to cause-specific mortality: A follow-up of 230,000 Norwegian adolescents. Am J Epidemiol 2008; 168: 30-7.

 

12. Bjørge T, Cnattingius S, Engeland A, Tretli S, Lie RT, Lukanova A. Fetal Down syndrome and the risk of maternal breast cancer. Epidemiology 2009; 20; 584-9.

 

13. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Concin H, Tretli S, Hallmans G, Jonsson H, Stattin P. Blood glucose and risk of incident and fatal cancer in the Metabolic syndrome and Cancer project (Me-Can): Analysis of six prospective cohorts. PLoS Med 2009; 6 (12): e1000201. DOI:10.1371/journal.pmed.1000201.

 

14. Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, Rapp K, Ulmer H, Almquist M, Concin H, Hallmans G, Jonsson H, Stattin P, Engeland A. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010; 171: 892-902.

 

15. Bjørge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Häggström C, Stattin P, Engeland A. Metabolic syndrome and breast cancer in the Me-Can (Metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010; 19: 1737-45.

 

16. Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Jonsson H, Häggström C, Stattin P, Engeland A. Metabolic syndrome and ovarian cancer in the Me-Can (Metabolic syndrome and cancer) project. Int J Epidemiol 2011; 40: 1667-77.

 

17. Ghaderi S, Engeland A, Moster D, Ruud E, Syse A, Wesenberg F, Bjørge T. Increased uptake of social security benefits among long-term survivors of cancer in childhood, adolescence and young adulthood: A Norwegian population-based cohort study. Br J Cancer 2013; 108: 1525-33.

 

18. de Vogel S, Meyer K, Fredriksen Å, Ulvik A, Ueland PM, Nygård O, Vollset SE, Tell GS, Tretli S, Bjørge T. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk. Int J Epidemiol 2013; 42: 201-10.

 

19. de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygård O, Vollset SE, Tell GS, Gregory JF, Tretli S, Bjørge T. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer – a large nested case-control study within the JANUS cohort in Norway. Int J Cancer 2014; 134: 197-206.

 

20. Bjørge T, Sørensen HT, Grotmol T, Engeland A, Stephansson O, Gissler M, Tretli S, Troisi R. Fetal growth and childhood cancer: A population-based study. Pediatrics 2013; 132: e1265-75.

 

  • Kreftrisiko i familier med barn med medfødte misdannelser
  • Forhold under graviditet og fødselskarakteristika i relasjon til kreft blant barn og ungdom
  • Metabolsk syndrom og kreft
  • Folatmetabolisme og kreft
  • Folat i graviditet og senere helserisiko for mor og barn
  • Langtidskonsekvenser av kreft blant barn og ungdom
  • Forhold under graviditet og kreft blant mødre
  • Cervixcancer epidemiologi

 

Lege, spesialist i patologi

Dr. med. i kreftepidemiologi

Kompetansefelt 

Forskergrupper